The SOC treatment regimen (5 days) was not altered to match the, initially approved, 3 day Brilacidin co-treatment. SOC remained constant, hence SOC. The difference now, following the scheduled pause and safety validation, is an approved increase of the Brilacidin dose from 3 to 5 days.

Hopefully, the additional testing sites will ensure the trial is completed to schedule.

Efficacy is our next hurdle.